Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study
Purpose: To determine the radiosensitizing effect of prolonged exposure of carboplatin in patients with locally unresectable non-small-cell lung cancer (NSCLC). Patients and methods: Patients with histologically proven NSCLC, performance score
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2004-03, Vol.15 (3), p.427-432 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 432 |
|---|---|
| container_issue | 3 |
| container_start_page | 427 |
| container_title | Annals of oncology |
| container_volume | 15 |
| creator | Groen, H. J. M. van der Leest, A. H. W. Fokkema, E. Timmer, P. R. Nossent, G. D. Smit, W. J. G. M. Nabers, J. Hoekstra, H. J. Hermans, J. Otter, R. van Putten, J. W. G. de Vries, E. G. E. Mulder, N. H. |
| description | Purpose: To determine the radiosensitizing effect of prolonged exposure of carboplatin in patients with locally unresectable non-small-cell lung cancer (NSCLC). Patients and methods: Patients with histologically proven NSCLC, performance score |
| doi_str_mv | 10.1093/annonc/mdh100 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdh100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_HXZ_W2G1PN88_0</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-540f32e3e95d0a9916c9fa15731e5619bc193a540842fff5178706c0dcfac5d73</originalsourceid><addsrcrecordid>eNpFkMFu1DAQhi1ERZfCkSvyhWOoHcdJzA2tSrtSRXsoAnGxZp0xNTjOypNILI_AU2PYFXsaaebzP-OPsVdSvJXCqEtIaUruchwepRBP2Erq1lS9aORTthKmVlWnVXPOnhN9F0K0pjbP2LlsjOn7plmx3-spzSEt00Jxz0PyC-HAHeTttItQJvxfA4hnGMJEmCjM4RfmwvI4OYjl2ZIyEroZthF5OaeisfQrhzHyuKRvJS85zO848HGJc3CY5pKwewRCvtlsOM3LsH_BzjxEwpfHesE-fbh6WN9Ut3fXm_X728opbeZKN8KrGhUaPQgwRrbOeJC6UxJ1K83WSaOgUH1Te--17PpOtE4MzoPTQ6cuWHXIdXkiyujtLocR8t5KYf86tQen9uC08K8P_G7Zjjic6KPEArw5AkBFiM_lt4FOnG7rplbqtDjQjD__zyH_sG2nOm1vvny1n-tref-x761QfwCo2pOx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Groen, H. J. M. ; van der Leest, A. H. W. ; Fokkema, E. ; Timmer, P. R. ; Nossent, G. D. ; Smit, W. J. G. M. ; Nabers, J. ; Hoekstra, H. J. ; Hermans, J. ; Otter, R. ; van Putten, J. W. G. ; de Vries, E. G. E. ; Mulder, N. H.</creator><creatorcontrib>Groen, H. J. M. ; van der Leest, A. H. W. ; Fokkema, E. ; Timmer, P. R. ; Nossent, G. D. ; Smit, W. J. G. M. ; Nabers, J. ; Hoekstra, H. J. ; Hermans, J. ; Otter, R. ; van Putten, J. W. G. ; de Vries, E. G. E. ; Mulder, N. H.</creatorcontrib><description>Purpose: To determine the radiosensitizing effect of prolonged exposure of carboplatin in patients with locally unresectable non-small-cell lung cancer (NSCLC). Patients and methods: Patients with histologically proven NSCLC, performance score <2, weight loss <10%, and normal organ functions were randomized between carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy or thoracic radiotherapy alone (both 60 Gy). Toxicity was evaluated with National Cancer Institute Common Toxicity Criteria (NCI CTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Quality of life was measured with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30/LC13 questionnaires. Results: One-hundred and sixty patients were included. Pathologically confirmed persistent tumor was present in 53% of patients in the combination arm versus 58% in the radiotherapy alone arm (P = 0.5). Median survival in the combination arm was 11.8 [95% confidence interval (CI) 9.3–14.2] months and in the radiotherapy alone arm 11.7 (95% CI 8.1–15.5) months; progression-free survival was not different between arms [6.8 and 7.5 months, respectively (P = 0.28)]. Acute toxicity was mild, late toxicity was radiation-induced cardiomyopathy (three patients) and pulmonary fibrosis (five patients). Quality of life was not different between arms, but in all measured patients cough and dyspnea improved, pain became less, and slight paresthesia developed 3 months after treatment. Conclusion: Addition of continuously administered carboplatin as radiosensitizer for locally unresectable NSCLC does not improve local tumor control or overall survival.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdh100</identifier><identifier>PMID: 14998844</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; carboplatin ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Infusions, Intravenous ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - radiotherapy ; Male ; Medical sciences ; Middle Aged ; NSCLC ; Pharmacology. Drug treatments ; Quality of Life ; Radiation-Sensitizing Agents - administration & dosage ; radiosensitization ; radiotherapy ; stage III ; Survival Rate ; Tumors</subject><ispartof>Annals of oncology, 2004-03, Vol.15 (3), p.427-432</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-540f32e3e95d0a9916c9fa15731e5619bc193a540842fff5178706c0dcfac5d73</citedby><cites>FETCH-LOGICAL-c359t-540f32e3e95d0a9916c9fa15731e5619bc193a540842fff5178706c0dcfac5d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15624233$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14998844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Groen, H. J. M.</creatorcontrib><creatorcontrib>van der Leest, A. H. W.</creatorcontrib><creatorcontrib>Fokkema, E.</creatorcontrib><creatorcontrib>Timmer, P. R.</creatorcontrib><creatorcontrib>Nossent, G. D.</creatorcontrib><creatorcontrib>Smit, W. J. G. M.</creatorcontrib><creatorcontrib>Nabers, J.</creatorcontrib><creatorcontrib>Hoekstra, H. J.</creatorcontrib><creatorcontrib>Hermans, J.</creatorcontrib><creatorcontrib>Otter, R.</creatorcontrib><creatorcontrib>van Putten, J. W. G.</creatorcontrib><creatorcontrib>de Vries, E. G. E.</creatorcontrib><creatorcontrib>Mulder, N. H.</creatorcontrib><title>Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Purpose: To determine the radiosensitizing effect of prolonged exposure of carboplatin in patients with locally unresectable non-small-cell lung cancer (NSCLC). Patients and methods: Patients with histologically proven NSCLC, performance score <2, weight loss <10%, and normal organ functions were randomized between carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy or thoracic radiotherapy alone (both 60 Gy). Toxicity was evaluated with National Cancer Institute Common Toxicity Criteria (NCI CTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Quality of life was measured with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30/LC13 questionnaires. Results: One-hundred and sixty patients were included. Pathologically confirmed persistent tumor was present in 53% of patients in the combination arm versus 58% in the radiotherapy alone arm (P = 0.5). Median survival in the combination arm was 11.8 [95% confidence interval (CI) 9.3–14.2] months and in the radiotherapy alone arm 11.7 (95% CI 8.1–15.5) months; progression-free survival was not different between arms [6.8 and 7.5 months, respectively (P = 0.28)]. Acute toxicity was mild, late toxicity was radiation-induced cardiomyopathy (three patients) and pulmonary fibrosis (five patients). Quality of life was not different between arms, but in all measured patients cough and dyspnea improved, pain became less, and slight paresthesia developed 3 months after treatment. Conclusion: Addition of continuously administered carboplatin as radiosensitizer for locally unresectable NSCLC does not improve local tumor control or overall survival.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>carboplatin</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>NSCLC</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality of Life</subject><subject>Radiation-Sensitizing Agents - administration & dosage</subject><subject>radiosensitization</subject><subject>radiotherapy</subject><subject>stage III</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMFu1DAQhi1ERZfCkSvyhWOoHcdJzA2tSrtSRXsoAnGxZp0xNTjOypNILI_AU2PYFXsaaebzP-OPsVdSvJXCqEtIaUruchwepRBP2Erq1lS9aORTthKmVlWnVXPOnhN9F0K0pjbP2LlsjOn7plmx3-spzSEt00Jxz0PyC-HAHeTttItQJvxfA4hnGMJEmCjM4RfmwvI4OYjl2ZIyEroZthF5OaeisfQrhzHyuKRvJS85zO848HGJc3CY5pKwewRCvtlsOM3LsH_BzjxEwpfHesE-fbh6WN9Ut3fXm_X728opbeZKN8KrGhUaPQgwRrbOeJC6UxJ1K83WSaOgUH1Te--17PpOtE4MzoPTQ6cuWHXIdXkiyujtLocR8t5KYf86tQen9uC08K8P_G7Zjjic6KPEArw5AkBFiM_lt4FOnG7rplbqtDjQjD__zyH_sG2nOm1vvny1n-tref-x761QfwCo2pOx</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>Groen, H. J. M.</creator><creator>van der Leest, A. H. W.</creator><creator>Fokkema, E.</creator><creator>Timmer, P. R.</creator><creator>Nossent, G. D.</creator><creator>Smit, W. J. G. M.</creator><creator>Nabers, J.</creator><creator>Hoekstra, H. J.</creator><creator>Hermans, J.</creator><creator>Otter, R.</creator><creator>van Putten, J. W. G.</creator><creator>de Vries, E. G. E.</creator><creator>Mulder, N. H.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20040301</creationdate><title>Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study</title><author>Groen, H. J. M. ; van der Leest, A. H. W. ; Fokkema, E. ; Timmer, P. R. ; Nossent, G. D. ; Smit, W. J. G. M. ; Nabers, J. ; Hoekstra, H. J. ; Hermans, J. ; Otter, R. ; van Putten, J. W. G. ; de Vries, E. G. E. ; Mulder, N. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-540f32e3e95d0a9916c9fa15731e5619bc193a540842fff5178706c0dcfac5d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>carboplatin</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>NSCLC</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality of Life</topic><topic>Radiation-Sensitizing Agents - administration & dosage</topic><topic>radiosensitization</topic><topic>radiotherapy</topic><topic>stage III</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Groen, H. J. M.</creatorcontrib><creatorcontrib>van der Leest, A. H. W.</creatorcontrib><creatorcontrib>Fokkema, E.</creatorcontrib><creatorcontrib>Timmer, P. R.</creatorcontrib><creatorcontrib>Nossent, G. D.</creatorcontrib><creatorcontrib>Smit, W. J. G. M.</creatorcontrib><creatorcontrib>Nabers, J.</creatorcontrib><creatorcontrib>Hoekstra, H. J.</creatorcontrib><creatorcontrib>Hermans, J.</creatorcontrib><creatorcontrib>Otter, R.</creatorcontrib><creatorcontrib>van Putten, J. W. G.</creatorcontrib><creatorcontrib>de Vries, E. G. E.</creatorcontrib><creatorcontrib>Mulder, N. H.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Groen, H. J. M.</au><au>van der Leest, A. H. W.</au><au>Fokkema, E.</au><au>Timmer, P. R.</au><au>Nossent, G. D.</au><au>Smit, W. J. G. M.</au><au>Nabers, J.</au><au>Hoekstra, H. J.</au><au>Hermans, J.</au><au>Otter, R.</au><au>van Putten, J. W. G.</au><au>de Vries, E. G. E.</au><au>Mulder, N. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>15</volume><issue>3</issue><spage>427</spage><epage>432</epage><pages>427-432</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Purpose: To determine the radiosensitizing effect of prolonged exposure of carboplatin in patients with locally unresectable non-small-cell lung cancer (NSCLC). Patients and methods: Patients with histologically proven NSCLC, performance score <2, weight loss <10%, and normal organ functions were randomized between carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy or thoracic radiotherapy alone (both 60 Gy). Toxicity was evaluated with National Cancer Institute Common Toxicity Criteria (NCI CTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Quality of life was measured with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30/LC13 questionnaires. Results: One-hundred and sixty patients were included. Pathologically confirmed persistent tumor was present in 53% of patients in the combination arm versus 58% in the radiotherapy alone arm (P = 0.5). Median survival in the combination arm was 11.8 [95% confidence interval (CI) 9.3–14.2] months and in the radiotherapy alone arm 11.7 (95% CI 8.1–15.5) months; progression-free survival was not different between arms [6.8 and 7.5 months, respectively (P = 0.28)]. Acute toxicity was mild, late toxicity was radiation-induced cardiomyopathy (three patients) and pulmonary fibrosis (five patients). Quality of life was not different between arms, but in all measured patients cough and dyspnea improved, pain became less, and slight paresthesia developed 3 months after treatment. Conclusion: Addition of continuously administered carboplatin as radiosensitizer for locally unresectable NSCLC does not improve local tumor control or overall survival.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>14998844</pmid><doi>10.1093/annonc/mdh100</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2004-03, Vol.15 (3), p.427-432 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdh100 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Biological and medical sciences carboplatin Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - radiotherapy Cisplatin - administration & dosage Combined Modality Therapy Disease-Free Survival Female Follow-Up Studies Humans Infusions, Intravenous Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - radiotherapy Male Medical sciences Middle Aged NSCLC Pharmacology. Drug treatments Quality of Life Radiation-Sensitizing Agents - administration & dosage radiosensitization radiotherapy stage III Survival Rate Tumors |
| title | Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A16%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuously%20infused%20carboplatin%20used%20as%20radiosensitizer%20in%20locally%20unresectable%20non-small-cell%20lung%20cancer:%20a%20multicenter%20phase%20III%20study&rft.jtitle=Annals%20of%20oncology&rft.au=Groen,%20H.%20J.%20M.&rft.date=2004-03-01&rft.volume=15&rft.issue=3&rft.spage=427&rft.epage=432&rft.pages=427-432&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdh100&rft_dat=%3Cistex_cross%3Eark_67375_HXZ_W2G1PN88_0%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14998844&rfr_iscdi=true |